127 related articles for article (PubMed ID: 25915108)
1. Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.
Loureiro AI; Bonifácio MJ; Fernandes-Lopes C; Pires N; Igreja B; Wright LC; Soares-da-Silva P
Xenobiotica; 2015; 45(9):828-39. PubMed ID: 25915108
[TBL] [Abstract][Full Text] [Related]
2. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: comparison with nepicastat.
Bonifácio MJ; Sousa F; Neves M; Palma N; Igreja B; Pires NM; Wright LC; Soares-da-Silva P
Eur J Pharmacol; 2015 Mar; 751():50-8. PubMed ID: 25641750
[TBL] [Abstract][Full Text] [Related]
4. Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in rat.
Loureiro AI; Bonifácio MJ; Fernandes-Lopes C; Igreja B; Wright LC; Soares-da-Silva P
Eur J Pharmacol; 2014 Oct; 740():285-94. PubMed ID: 25058908
[TBL] [Abstract][Full Text] [Related]
5. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase.
Stanley WC; Li B; Bonhaus DW; Johnson LG; Lee K; Porter S; Walker K; Martinez G; Eglen RM; Whiting RL; Hegde SS
Br J Pharmacol; 1997 Aug; 121(8):1803-9. PubMed ID: 9283721
[TBL] [Abstract][Full Text] [Related]
6. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
Kallem R; Kulkarni CP; Patel D; Thakur M; Sinz M; Singh SP; Mahammad SS; Mandlekar S
Drug Metab Lett; 2012 Jun; 6(2):134-44. PubMed ID: 23061481
[TBL] [Abstract][Full Text] [Related]
7. Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine β-hydroxylase inhibitor, in healthy subjects.
Rocha JF; Vaz-Da-Silva M; Nunes T; Igreja B; Loureiro AI; Bonifácio MJ; Wright LC; Falcão A; Almeida L; Soares-Da-Silva P
J Clin Pharmacol; 2012 Feb; 52(2):156-70. PubMed ID: 21343348
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat.
Pires NM; Igreja B; Moura E; Wright LC; Serrão MP; Soares-da-Silva P
Hypertens Res; 2015 Sep; 38(9):605-12. PubMed ID: 25854989
[TBL] [Abstract][Full Text] [Related]
9. Liposomes Coloaded with Elacridar and Tariquidar To Modulate the P-Glycoprotein at the Blood-Brain Barrier.
Nieto Montesinos R; Béduneau A; Lamprecht A; Pellequer Y
Mol Pharm; 2015 Nov; 12(11):3829-38. PubMed ID: 26390138
[TBL] [Abstract][Full Text] [Related]
10. Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.
Almeida L; Nunes T; Costa R; Rocha JF; Vaz-da-Silva M; Soares-da-Silva P
Clin Ther; 2013 Dec; 35(12):1983-96. PubMed ID: 24296323
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor.
Pires NM; Loureiro AI; Igreja B; Lacroix P; Soares-da-Silva P
Eur J Pharmacol; 2015 Mar; 750():98-107. PubMed ID: 25641747
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P
Clin Ther; 2011 Jun; 33(6):776-91. PubMed ID: 21704242
[TBL] [Abstract][Full Text] [Related]
13. N-acetylation of etamicastat, a reversible dopamine-β-hydroxylase inhibitor.
Loureiro AI; Fernandes-Lopes C; Bonifácio MJ; Wright LC; Soares-da-Silva P
Drug Metab Dispos; 2013 Dec; 41(12):2081-6. PubMed ID: 24013186
[TBL] [Abstract][Full Text] [Related]
14. pH Dependent but not P-gp Dependent Bidirectional Transport Study of S-propranolol: The Importance of Passive Diffusion.
Zheng Y; Benet LZ; Okochi H; Chen X
Pharm Res; 2015 Aug; 32(8):2516-26. PubMed ID: 25690341
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects.
Nunes T; Rocha JF; Vaz-da-Silva M; Igreja B; Wright LC; Falcão A; Almeida L; Soares-da-Silva P
Drugs R D; 2010; 10(4):225-42. PubMed ID: 21171669
[TBL] [Abstract][Full Text] [Related]
16. Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution.
Montesinos RN; Moulari B; Gromand J; Beduneau A; Lamprecht A; Pellequer Y
Drug Metab Dispos; 2014 Apr; 42(4):700-6. PubMed ID: 24398461
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
Sane R; Mittapalli RK; Elmquist WF
J Pharm Sci; 2013 Apr; 102(4):1343-54. PubMed ID: 23334925
[TBL] [Abstract][Full Text] [Related]
18. P-Glycoprotein (ABCB1) limits the brain distribution of YQA-14, a novel dopamine D3 receptor antagonist.
Liu F; Wang X; Li Z; Li J; Zhuang X; Zhang Z
Chem Pharm Bull (Tokyo); 2015; 63(7):512-8. PubMed ID: 26133067
[TBL] [Abstract][Full Text] [Related]
19. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
20. Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453).
Vaz-da-Silva M; Nunes T; Rocha JF; Falcão A; Almeida L; Soares-da-Silva P
Drugs R D; 2011; 11(2):127-36. PubMed ID: 21548660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
